Arcadia Therapeutics
ASD (autism spectrum disorder) has now reached an alarming prevalence of 1 in 36, marking a significant 22% surge in reported prevalence rates by the CDC since 2021. At Arcadia Therapeutics (AT), we are committed to advancing understanding, supporting innovative research, and providing vital therapeutics for those living with ASD. We believe that current treatments with OT, PT, Speech, ABA, and feeding therapy are merely a band-aid that do not ultimately alter the ASD process at a cellular level. At Arcadia, we look forward to using novel therapies to see if we can alter ASD at a cellular level with new treatments that can help children that traditional medicine has left with no options.
7-day free trial · no credit card
Verified contacts
2
available on Kipplo
LinkedIn employees
2
11 to 50 range
Open roles
—
no listings
Distinct roles
2
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 2 verified contacts at Arcadia Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
2 contacts with verified email or phone · masked until revealed.
Showing 1 of 2 verified contacts
Top roles at Arcadia Therapeutics
2 distinct titles indexed · top 2 shown.
- 1chief executive officer
- 1principal scientist
Sign up to unlock all 2 contacts at Arcadia Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 2 verified contacts at Arcadia Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.